NCT03098589已完成不适用
Revlimid® Capsules Drug Use-results Surveillance Relapsed or Refractory Adult T-cell Leukemia Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Celgene
- 入组人数
- 1,149
- 试验地点
- 1
- 主要终点
- Adverse Events (AEs)
研究概览
简要总结
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)).
- Planned registration period 3 years
- Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Relapsed or Refractory Adult T-cell Leukemia Lymphoma
排除标准
- 未提供
研究组 & 干预措施
Patients with T-cell leukemia lymphoma treated with Revlimid
Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
干预措施: Revlimid (Drug)
结局指标
主要结局
Adverse Events (AEs)
时间窗: Up to approximately 4 years
Number of participants with adverse events
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])Multiple MyelomaNCT02741544Celgene578
已完成
不适用
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)Lymphoma NonhodgkinNCT04618081Celgene151
已完成
不适用
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseMultiple MyelomaNCT02922543Celgene361
已完成
不适用
A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesMyelodysplastic SyndromesMultiple MyelomaNCT02921802Celgene4,626
已完成
2 期
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChronic Lymphocytic Leukemia (CLL)Small Lymphocytic LymphomaNCT00439231Georg Aue, M.D.33